Lung scarring management

Lung scarring, also referred to as pulmonary fibrosis or interstitial lung scarring, develops as a result of chronic inflammation or injury that leads to deposition of fibrotic tissue within the lungs. Causes include autoimmune diseases, environmental exposures, infections, radiation therapy, and adverse drug reactions. The consequences are reduced lung elasticity, impaired oxygen exchange, and progressive shortness of breath. Lung scarring management is complex, as established fibrosis cannot be reversed, but interventions can slow its progression and improve patient quality of life. Pharmacologic options such as antifibrotic drugs help reduce further scarring, while corticosteroids and immunosuppressants may be useful when inflammation is active. Pulmonary rehabilitation programs strengthen physical endurance and provide patients with coping strategies for breathlessness. Oxygen therapy, vaccination, and meticulous infection prevention are additional pillars of care. In advanced cases, lung transplantation remains the definitive treatment option, though it is limited by eligibility and organ availability. Researchers are exploring regenerative approaches, including stem cell therapy and molecular inhibitors that target specific fibrotic pathways. Equally important is psychosocial support, as chronic lung scarring often imposes emotional and social burdens. A multidisciplinary, proactive approach to lung scarring management offers the best chance of maintaining stability, delaying progression, and preserving functional independence in affected individuals.